Stephen Russell

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint The utility of cells as vehicles for oncolytic virus therapies
    Stephen J Russell
    Mayo Clinic, Department of Molecular Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Opin Mol Ther 10:380-6. 2008
  2. pmc Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer
    Emily K Mader
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 11:20. 2013
  3. pmc Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine
    Brian Hutzen
    The Ohio State University, Columbus, OH 43205, USA
    BMC Cancer 12:508. 2012
  4. doi request reprint Oncolytic virotherapy
    Stephen J Russell
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Nat Biotechnol 30:658-70. 2012
  5. ncbi request reprint Modifying the host range properties of retroviral vectors
    S J Russell
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    J Gene Med 1:300-11. 1999
  6. ncbi request reprint Measles virus for cancer therapy
    S J Russell
    Mayo Clinic, Department of Molecular Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Top Microbiol Immunol 330:213-41. 2009
  7. ncbi request reprint RNA viruses as virotherapy agents
    Stephen J Russell
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Gene Ther 9:961-6. 2002
  8. pmc Viruses as anticancer drugs
    Stephen J Russell
    Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Trends Pharmacol Sci 28:326-33. 2007
  9. ncbi request reprint Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression
    Louay K Hallak
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 65:5292-300. 2005
  10. ncbi request reprint Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter
    Kosei Hasegawa
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:1868-75. 2006

Research Grants

  1. Antibody Neutralization of Therapeutic Viruses
    Stephen J Russell; Fiscal Year: 2010
  2. Radiovirotherapy for Multiple Myeloma
    Stephen Russell; Fiscal Year: 2007
  3. TARGETING ANGIOGENESIS WITH PROTEASE ACTIVATABLE VECTORS
    Stephen Russell; Fiscal Year: 2002
  4. Radiovirotherapy for Multiple Myeloma
    Stephen J Russell; Fiscal Year: 2010

Detail Information

Publications88

  1. ncbi request reprint The utility of cells as vehicles for oncolytic virus therapies
    Stephen J Russell
    Mayo Clinic, Department of Molecular Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Opin Mol Ther 10:380-6. 2008
    ..Aside from their virus chaperoning capabilities, certain carrier cell types may exert additional antitumor activities that operate in synergy with the oncolytic virus infection to mediate tumor regression...
  2. pmc Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer
    Emily K Mader
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    J Transl Med 11:20. 2013
    ..In preparation for a clinical trial to use MSC as MV carriers, we obtained cells from ovarian cancer patients and evaluated feasibility and safety of this approach...
  3. pmc Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine
    Brian Hutzen
    The Ohio State University, Columbus, OH 43205, USA
    BMC Cancer 12:508. 2012
    ....
  4. doi request reprint Oncolytic virotherapy
    Stephen J Russell
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Nat Biotechnol 30:658-70. 2012
    ....
  5. ncbi request reprint Modifying the host range properties of retroviral vectors
    S J Russell
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    J Gene Med 1:300-11. 1999
    ..The strengths and limitations of these strategies are examined...
  6. ncbi request reprint Measles virus for cancer therapy
    S J Russell
    Mayo Clinic, Department of Molecular Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Curr Top Microbiol Immunol 330:213-41. 2009
    ..Clinical trials testing oncolytic measles viruses as an experimental cancer therapy are currently underway...
  7. ncbi request reprint RNA viruses as virotherapy agents
    Stephen J Russell
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Gene Ther 9:961-6. 2002
    ....
  8. pmc Viruses as anticancer drugs
    Stephen J Russell
    Molecular Medicine Program, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Trends Pharmacol Sci 28:326-33. 2007
    ..This review introduces concepts relevant to the use of viruses as anticancer drugs, emphasizing targeting mechanisms as well as safety and efficacy issues that are currently limiting their clinical success...
  9. ncbi request reprint Targeted measles virus vector displaying echistatin infects endothelial cells via alpha(v)beta3 and leads to tumor regression
    Louay K Hallak
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 65:5292-300. 2005
    ..The specificity, potency, and feasibility of MV-ERV infection clearly show the potential use of MV-ERV in gene therapy for targeting tumor-associated vasculature for the treatment of solid tumors...
  10. ncbi request reprint Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter
    Kosei Hasegawa
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Clin Cancer Res 12:1868-75. 2006
    ..Because of the unfavorable replication kinetics of measles viruses expressing both CEA and NIS, we explored the feasibility of combining MV-CEA with MV-NIS for comprehensive virotherapy monitoring in ovarian cancer...
  11. ncbi request reprint Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme
    Loi K Phuong
    Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 63:2462-9. 2003
    ..c. and orthotopic U87 animal models. Monitoring CEA levels in the serum can serve as a low-risk method of detecting viral gene expression during treatment, and could allow dose optimization and individualization of treatment...
  12. ncbi request reprint Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas
    Georgia Paraskevakou
    Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Mol Ther 15:677-86. 2007
    ....
  13. ncbi request reprint Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, MN 55905, USA
    Blood 103:1641-6. 2004
    ..Testing in other radiosensitive cancers is warranted...
  14. ncbi request reprint A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer
    Cari J McDonald
    Molecular Medicine Program, Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 99:177-84. 2006
    ..Trackable measles virus derivatives merit further exploration in breast cancer treatment...
  15. pmc Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
    Francesca Gay
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 115:1343-50. 2010
    ..3% vs 9.2%, P = .058) and peripheral neuropathy (10.4% vs 0.9%, P < .001). Len/dex appears well-tolerated and more effective than thal/dex. Randomized trials are needed to confirm these results...
  16. ncbi request reprint Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides
    Kah Whye Peng
    Molecular Medicine Program, Mayo Foundation, Rochester, Minnesota, USA
    Nat Med 8:527-31. 2002
    ..Oncolytic viruses expressing inert soluble marker polypeptides should greatly facilitate the rational development of effective, individually tailored cancer virotherapy...
  17. pmc Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model
    Ianko D Iankov
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res Treat 122:745-54. 2010
    ..This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer...
  18. pmc Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter
    Pavlos Msaouel
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 17:2041-8. 2009
    ..The NIS transgene allows viral localization and monitoring by noninvasive imaging which can facilitate dose optimization in a clinical setting...
  19. pmc Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma
    Kah Whye Peng
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 84:401-7. 2009
    ..Thus, TAM are a universal stromal component of the plasmacytomas of myeloma patients and may offer a promising new target for therapeutic exploitation. Am. J. Hematol. 2009. (c) 2009 Wiley-Liss, Inc...
  20. pmc Engineered measles virus as a novel oncolytic therapy against prostate cancer
    Pavlos Msaouel
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Prostate 69:82-91. 2009
    ..In this study, we investigated the antitumor potential of recombinant MV-Edm derivatives as novel oncolytic agents against prostate cancer...
  21. ncbi request reprint Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mol Imaging Biol 8:16-23. 2006
    ..We evaluated the potential of I-124 positron emission tomography (PET)/computed tomography (CT) imaging in gene therapy animal models utilizing the sodium iodide symporter (NIS) and compared the findings to I-123 gamma camera imaging...
  22. pmc Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene
    Apollina Goel
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 110:2342-50. 2007
    ..These results show that VSV(Delta51)-NIS is a safe oncolytic agent with significant therapeutic potential in multiple myeloma...
  23. pmc Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model
    Emily K Mader
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 15:7246-55. 2009
    ..Hence, we hypothesized that measles virotherapy of ovarian cancer in measles-immune mice might be superior if MV-infected mesenchymal stem cell (MSC) carriers are used...
  24. pmc Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity
    Cory Allen
    Molecular Medicine Department, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Mol Ther 16:1556-64. 2008
    ..Strains of measles virus retargeted against the glioma-specific IL-13Ralpha2 receptor have comparable therapeutic efficacy, and improved specificity as compared with the unmodified measles virus strain MV-GFP in vitro and in vivo...
  25. ncbi request reprint Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy
    Ianko D Iankov
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 15:114-22. 2007
    ..These results suggest a novel strategy for systemic delivery of oncolytic virotherapy in cancer patients that can "bypass" the pre-existing humoral immunity against MV...
  26. ncbi request reprint Antibody-targeted cell fusion
    Takafumi Nakamura
    Molecular Medicine Program, Mayo Foundation, 200 First St SW, Rochester, Minnesota 55905, USA
    Nat Biotechnol 22:331-6. 2004
    ....
  27. ncbi request reprint High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus
    Bambi D Anderson
    Molecular Medicine Program, Mayo Clinic Cancer Center, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Res 64:4919-26. 2004
    ..Discrimination between high and low CD46 receptor density provides a compelling basis for the oncolytic specificity of MV-Edm and establishes MV-Edm as a promising CD46-targeted cancer therapeutic agent...
  28. ncbi request reprint Genetically targeted radiotherapy for multiple myeloma
    David Dingli
    Mayo Clinic and Foundation, Rochester, MN, USA
    Blood 102:489-96. 2003
    ..We conclude that lentivectors can be transcriptionally targeted for myeloma cells and the use of hNIS as a therapeutic gene for myeloma in combination with 131I needs further exploration...
  29. ncbi request reprint Intraperitoneal therapy of ovarian cancer using an engineered measles virus
    Kah Whye Peng
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:4656-62. 2002
    ..Trackable recombinant measles viruses warrant further investigation for therapy of ovarian cancer...
  30. pmc Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer
    Alan R Penheiter
    Department of Molecular Medicine, Mayo Clinic, Rochester, MN 55905, USA
    AJR Am J Roentgenol 195:341-9. 2010
    ..The goal of this study was to determine the synergy between MV-NIS-induced oncolysis and NIS-mediated (131)I radiotherapy in this tumor model...
  31. ncbi request reprint Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity
    Cory Allen
    Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 66:11840-50. 2006
    ....
  32. ncbi request reprint Engineering oncolytic measles virus to circumvent the intracellular innate immune response
    Iana Haralambieva
    1Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Mol Ther 15:588-97. 2007
    ..These results indicate that oncolytic viruses are subject to control by the innate immune defenses of human tumor cells and may therefore be more effective if their natural ability to combat innate immunity is maintained...
  33. pmc Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer
    Chunsheng Liu
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Prostate 69:1128-41. 2009
    ....
  34. ncbi request reprint Mathematical modeling of cancer radiovirotherapy
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Math Biosci 199:55-78. 2006
    ..Furthermore, we evaluated relevant therapeutic scenarios for radiovirotherapy, and offered elements for optimization...
  35. ncbi request reprint Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma
    Boris Blechacz
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    Hepatology 44:1465-77. 2006
    ..MV-Edm expressing CEA or hNIS elicited oncolytic effects in human HCC cell lines in vitro and in vivo, enabling the spread of the virus to be monitored in a noninvasive manner...
  36. pmc Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma
    Kristen Detweiler-Short
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:737-40. 2010
    ..Grade 3-4 nonhematologic adverse events were noted in 55% of patients. Randomized trials are needed to determine the role of early therapy in SMM...
  37. pmc Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone
    Prashant Kapoor
    Department of Internal Medicine, Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Blood 114:518-21. 2009
    ..These results need confirmation in larger, prospectively designed studies...
  38. ncbi request reprint Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas
    Cory Allen
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Gene Med 6:1216-27. 2004
    ..Given the high frequency of MMP overexpression in gliomas, AdM40 represents a potentially promising agent in the gene therapy of these tumors...
  39. ncbi request reprint Reengineering paramyxovirus tropism
    Elizabeth M Hadac
    Molecular Medicine Program, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Virology 329:217-25. 2004
    ..We conclude that paramyxoviruses have a remarkably flexible and adaptable entry mechanism...
  40. ncbi request reprint Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme
    Chunsheng Liu
    Molecular Medicine Program, Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:7155-65. 2007
    ..Radiation therapy (RT) represents one of the mainstays of glioma treatment. Here we tested the hypothesis that the combination of RT with MV-CEA would have synergistic activity against gliomas...
  41. pmc Converting tumor-specific markers into reporters of oncolytic virus infection
    Ianko D Iankov
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Mol Ther 17:1395-403. 2009
    ..This is the first report of a gene therapy vector engineered to discriminate between infection in malignant and normal cells by molecular modification of a tumor-specific protein...
  42. ncbi request reprint Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein
    Jie Zhang
    Mayo Clinic, Molecular Medicine Program, 200 First Street, SW, Rochester, MN 55905, USA
    J Gene Med 6:1082-91. 2004
    ..In addition, Sindbis virus nonstructural proteins are potent inducers of apoptosis, and Sindbis vector RNAs expressing fusogenic viral proteins have been shown to spread from cell-to-cell in membrane-formed infectious particles...
  43. ncbi request reprint Oncolytic measles viruses for cancer therapy
    Takafumi Nakamura
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Expert Opin Biol Ther 4:1685-92. 2004
    ..Further improvements in existing MV vectors may increase tumour selectivity and oncolytic activity. This review discusses the discovery and development of replication-competent oncolytic MV for cancer therapy...
  44. ncbi request reprint Native osteoprotegerin gene transfer inhibits the development of murine osteolytic bone disease induced by tumor xenografts
    Patrick M Doran
    Molecular Medicine Program, Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
    Exp Hematol 32:351-9. 2004
    ..In order to overcome these limitations, the therapeutic effects of native OPG gene transfer are examined...
  45. pmc Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo
    Hooi Tin Ong
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Ther 17:1012-21. 2009
    ..To our knowledge, this is the first report demonstrating that oncolytic MVs can be engineered to target the lumenal endothelial surface of newly formed blood vessels when administered intravenously in living animals...
  46. ncbi request reprint Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer
    Rae Myers
    Toxicology Core, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Cancer Gene Ther 12:593-9. 2005
    ..All three viruses demonstrated equivalent antitumor potency. Commercially available Moraten measles and Jeryl-Lynn mumps vaccines warrant further investigation as potential anticancer agents...
  47. ncbi request reprint Oncolytic measles virus targets high CD46 expression on multiple myeloma cells
    Hooi Tin Ong
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Exp Hematol 34:713-20. 2006
    ..In this study, we investigated the potential of CD46 as a target for MM therapy and correlated surface levels of CD46 on MM cells with their susceptibility to MV-induced cytopathic effects...
  48. pmc Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component
    John A Lust
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 84:114-22. 2009
    ..To conduct in vitro studies as well as a phase 2 clinical trial in patients with smoldering or indolent multiple myeloma to determine if interleukin 1 (IL-1) inhibitors can delay or prevent active myeloma...
  49. pmc Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer
    Evanthia Galanis
    Division of Medical Oncology, Department of Molecular Medicine, Mayo Clinic, Gonda 10 141, 200 First Street Southwest, Rochester, MN 55905, USA
    Cancer Res 70:875-82. 2010
    ..Our findings indicate that i.p. administration of MV-CEA is well tolerated and results in dose-dependent biological activity in a cohort of heavily pretreated recurrent ovarian cancer patients...
  50. pmc Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats
    Alessandro Cataliotti
    Molecular Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Circulation 123:1297-305. 2011
    ..In the current study, we tested the effects of sustained cardiac proBNP gene delivery on BP, cardiac function, and remodeling in spontaneously hypertensive rats (SHR)...
  51. pmc Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    Shaji K Kumar
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1095-110. 2009
    ..This set of recommendations represents such an effort-the development of a set of consensus guidelines by a group of experts to manage patients with newly diagnosed disease based on an interpretation of the best available evidence...
  52. pmc Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905
    Mayo Clin Proc 86:12-8. 2011
    ..To examine whether the outcome of patients with primary systemic amyloidosis (AL) has improved over time and to identify predictors of early mortality in patients with AL...
  53. pmc Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines
    Stephen M Ansell
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 85:824-33. 2010
    ..Autologous stem cell transplant should be considered in all eligible patients with relapsed disease...
  54. doi request reprint Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Nephrol Dial Transplant 24:3132-7. 2009
    ..The kidney is affected by immunoglobulin light chain amyloidosis (AL) in more than 50% of patients who present with the disease, but long-term predictors for and outcomes after renal replacement therapy are not well described...
  55. pmc Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
    Angela Dispenzieri
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:757-9. 2010
    ....
  56. pmc Concordant activity of transgene expression cassettes inserted into E1, E3 and E4 cloning sites in the adenovirus genome
    Linh Pham
    Department of Molecular Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    J Gene Med 11:197-206. 2009
    ....
  57. ncbi request reprint In vivo quantitation of intratumoral radioisotope uptake using micro-single photon emission computed tomography/computed tomography
    Stephanie K Carlson
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 559005, USA
    Mol Imaging Biol 8:324-32. 2006
    ....
  58. ncbi request reprint Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 81:1047-53. 2006
    ..These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits...
  59. pmc Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response
    Ianko D Iankov
    Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    J Virol 80:8530-40. 2006
    ..The findings point to a new model for the pathogenesis of atypical MV infection observed after immunization with formalin-inactivated MV vaccine and underscore the importance of the anti-F response after vaccination...
  60. ncbi request reprint The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
    Angela Dispenzieri
    Department of Biostatistics, Mayo Clinic, Rochester, MN 55905, USA
    Blood 109:465-70. 2007
    ..In AL patients, we saw limited activity of single-agent lenalidomide, but significant activity of the combination with dexamethasone, which warrants further investigation...
  61. pmc Improved survival in multiple myeloma and the impact of novel therapies
    Shaji K Kumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2516-20. 2008
    ..8 vs 29.9 months; P < .001). In this study, we demonstrate improved outcome of patients with myeloma in recent years, both in the relapsed setting as well as at diagnosis...
  62. ncbi request reprint Small animal absorbed radiation dose from serial micro-computed tomography imaging
    Stephanie K Carlson
    Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mol Imaging Biol 9:78-82. 2007
    ..To determine the radiation dose to mouse cancer xenografts from serial micro-computed tomography (CT) examinations...
  63. ncbi request reprint Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement
    Angela Dispenzieri
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:323-41. 2007
    ....
  64. ncbi request reprint Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma
    Martha Q Lacy
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:1179-84. 2007
    ..To determine the long-term effects of a combined regimen of lenalidomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma...
  65. pmc Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 106:4050-3. 2005
    ..Rev/Dex is a highly active regimen with manageable side effects in the treatment of newly diagnosed myeloma...
  66. ncbi request reprint A preclinical large animal model of adenovirus-mediated expression of the sodium-iodide symporter for radioiodide imaging and therapy of locally recurrent prostate cancer
    Roisin M Dwyer
    Department of Endocrinology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Mol Ther 12:835-41. 2005
    ..The results presented provide further evidence of the safety and efficacy of NIS as a therapeutic gene and support translation of this work into the clinical setting...
  67. ncbi request reprint Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker
    Kah Whye Peng
    Molecular Medicine Program, Mayo Foundation, Rochester, MN 55905, USA
    Blood 101:2557-62. 2003
    ..Tumorigenicity of CHO-CD38 cells in immunocompromised mice was significantly attenuated by MV-alpha CD38, resulting in enhanced survival of these mice compared with the control group...
  68. ncbi request reprint Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis
    S Vincent Rajkumar
    Division of Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:2210-6. 2002
    ..To determine whether bone marrow (BM) angiogenesis progressively increases along the spectrum of plasma cell disorders ranging from monoclonal gammopathy of undetermined significance (MGUS) to advanced myeloma...
  69. ncbi request reprint Dynamic iodide trapping by tumor cells expressing the thyroidal sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 325:157-66. 2004
    ..Iodide organification was insignificant. In vivo studies in tumors composed of mixed cell populations confirmed these observations...
  70. ncbi request reprint Rise of the nanomachines
    Stephen J Russell
    Nat Biotechnol 21:872-3. 2003
  71. ncbi request reprint Parvovirus vectors: use and optimisation in cancer gene therapy
    Boris Blechacz
    Molecular Medicine Program, Mayo Clinic, 200 First Street SW, Guggenheim 18 33, Rochester, MN 55905, USA
    Expert Rev Mol Med 6:1-24. 2004
    ..This article evaluates their usefulness in gene therapy strategies for cancer...
  72. ncbi request reprint In vivo imaging and tumor therapy with the sodium iodide symporter
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, Minnesota 55905, USA
    J Cell Biochem 90:1079-86. 2003
    ..In this review, we discuss the role of the sodium iodide symporter (NIS) as a reporter and therapeutic gene for cancer gene therapy when combined with various radioactive isotopes...
  73. pmc Non-invasive radioiodine imaging for accurate quantitation of NIS reporter gene expression in transplanted hearts
    Davide Ricci
    Mayo Clinic William J von Liebig Transplant Center, Rochester, MN 55905, USA
    Eur J Cardiothorac Surg 33:32-9. 2008
    ....
  74. ncbi request reprint Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar-CD46Ge transgenic mice
    Kah Whye Peng
    Molecular Medicine Program, Guggenheim 18, Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Hum Gene Ther 14:1565-77. 2003
    ....
  75. pmc Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation
    Noel M Caplice
    Division of Cardiovascular Diseases, Molecular Medicine Program, Mayo Clinic, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 100:4754-9. 2003
    ..These data have broad implications for our understanding of the cellular components of human atherosclerotic plaque and provide a potentially novel target for future diagnostic and therapeutic strategies...
  76. ncbi request reprint Promising preclinical activity of 2-methoxyestradiol in multiple myeloma
    David Dingli
    Molecular Medicine Program, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Clin Cancer Res 8:3948-54. 2002
    ..There are limited treatment options for patients with multiple myeloma (MM) who relapse after high-dose therapy and stem cell transplantation. We studied the preclinical activity of 2ME2 as a therapeutic agent for myeloma...
  77. ncbi request reprint Rescue and propagation of fully retargeted oncolytic measles viruses
    Takafumi Nakamura
    Nat Biotechnol 23:209-14. 2005
    ..These data provide an in vivo demonstration of antibody-directed tumor destruction by retargeted oncolytic viruses...
  78. ncbi request reprint PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis
    Apollina Goel
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Exp Hematol 33:784-95. 2005
    ..We investigated the potential of enhancing the radiosensitivity of myeloma cells by combining with PS-341; the underlying mechanisms were delineated...
  79. pmc Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation
    Angela Dispenzieri
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 107:3378-83. 2006
    ..Achievement of FLC response was a better predictor of survival than achievement of complete hematologic response or normalization of the FLC ratio. FLC measurements both before and after PBSCT are important predictors of patient outcome...
  80. doi request reprint Modeling of cancer virotherapy with recombinant measles viruses
    Zeljko Bajzer
    Biomathematics Resource and Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Guggenheim 1611b, Rochester, MN 55905, USA
    J Theor Biol 252:109-22. 2008
    ..The model exhibits damped, as well as stable oscillations in a range of parameter values. These oscillatory states are organized by a Hopf bifurcation...
  81. ncbi request reprint Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide
    Marielle Maurice
    Laboratoire Vectorologie Rétrovirale et Thérapie Génique, Unité de Virologie Humaine, U412 INSERM, IFR 74 and ENS de Lyon, 46 allee d Italie, 69364 Lyon Cedex 07, France
    Blood 99:2342-50. 2002
    ..Moreover these results provide a proof of concept for an approach that may have utility in various gene transfer applications, including in vivo gene delivery...
  82. ncbi request reprint Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions
    Judit Szecsi
    INSERM U758, 69364 Lyon, France
    Mol Ther 14:735-44. 2006
    ..These vectors will allow useful gene transfer applications into target cells exhibiting specific protease activities...
  83. pmc Synergistic activity of the proteasome inhibitor PS-341 with non-myeloablative 153-Sm-EDTMP skeletally targeted radiotherapy in an orthotopic model of multiple myeloma
    Apollina Goel
    Molecular Medicine Program, College of Medicine, Mayo Clinic, Guggenheim 1833, 200 First Street SW, Rochester, MN 55905, USA
    Blood 107:4063-70. 2006
    ..PS-341 is a potent, selective in vivo radiosensitizer that may substantially affect the efficacy of skeletal-targeted radiotherapy in multiple myeloma...
  84. ncbi request reprint Interaction of measles virus vectors with Auger electron emitting radioisotopes
    David Dingli
    Molecular Medicine Program, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 337:22-9. 2005
    ..MV-NICE does not replicate faster in the presence of radiation. Auger electron emitting isotopes effectively stop propagation of MV vectors expressing NIS in vitro. Additional work is necessary to translate these observations in vivo...
  85. ncbi request reprint Ex vivo hypothermic recirculatory adenoviral gene transfer to the transplanted pig heart
    Keiji Oi
    Mayo Clinic William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN 55905, USA
    J Gene Med 8:795-803. 2006
    ..To facilitate the application of adenoviral gene therapy in clinical heart transplantation, we developed an ex vivo hypothermic recirculatory adenoviral gene transfer method to the transplanted pig heart...
  86. pmc Oncolytic measles virus strains in the treatment of gliomas
    Cory Allen
    Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA
    Expert Opin Biol Ther 8:213-20. 2008
    ..Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy...
  87. doi request reprint Sodium iodide symporter (hNIS) permits molecular imaging of gene transduction in cardiac transplantation
    Vinay P Rao
    William J von Liebig Transplant Center, Department of Surgery, Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, USA
    Transplantation 84:1662-6. 2007
    ....
  88. ncbi request reprint Recombinant adeno-associated virus vector for gene transfer to the transplanted rat heart
    Johannes M Schirmer
    William J von Liebig Transplant Center, Mayo Clinic, Rochester, MN 55905, USA
    Transpl Int 20:550-7. 2007
    ..This study demonstrates cardiac rAAV gene transduction with a cold perfusion preservation system of the donor heart. These data show that AAV-1 is superior to AAV-2 and AAV-5 for this purpose and that durable expression is achievable...

Research Grants15

  1. Antibody Neutralization of Therapeutic Viruses
    Stephen J Russell; Fiscal Year: 2010
    ..Public Health Relevance: Antibodies are the most important barrier to the successful deployment of viruses as anticancer agents. This grant seeks to develop clinical viable solutions to this problem. ..
  2. Radiovirotherapy for Multiple Myeloma
    Stephen Russell; Fiscal Year: 2007
    ..4. With correct tailoring of the dose and timing of 131I administration the therapeutic benefit of MV-NIS radiovirotherapy will be greater than the benefit of MV-Edm virotherapy alone. ..
  3. TARGETING ANGIOGENESIS WITH PROTEASE ACTIVATABLE VECTORS
    Stephen Russell; Fiscal Year: 2002
    ..abstract_text> ..
  4. Radiovirotherapy for Multiple Myeloma
    Stephen J Russell; Fiscal Year: 2010
    ..The studies to be pursued in this grant combine the promising novel approach of oncolytic virotherapy with the use of radioactive iodine for the treatment of this disease. ..